Roche has recently seen its shares climb due to the successful early stage trials of its
weight-loss drug. Furthermore, Zacks Analyst Blog has recently highlighted Roche along with other notable stocks like Novo Nordisk, Eli Lilly's, Viking, etc. The question has been raised regarding the current undervaluation of Roche's stock at $33, while the company continues to make strides in research. The
ownership of Roche Holding AG's share holds 55% stake by individual investors and 36% by institutions. Despite research setbacks and a drop in sales, Roche's
cancer drug has gained the 'Breakthrough Therapy Designation'. Recent
obesity drug results from early-stage trials have resulted in an uptick in Roche shares. Roche's Q1 sales were slightly down, which resonated with the downward trend of the stock, but the company's outlook for FY24 was confirmed. Amid all this, Roche has managed to purchase an obesity drug maker for $3.1 billion. However, certain investors experienced a loss of 18% over the last
three years. It is worth noting that Roche's dividend will increase to CHF9.60.
Roche Stocks News Analytics from Mon, 21 Aug 2023 07:00:00 GMT to Thu, 23 May 2024 04:52:30 GMT -
Rating 3
- Innovation -2
- Information 6
- Rumor 1
